Comparing Poor and Favorable Outcome Prediction With Machine Learning After Mechanical Thrombectomy in Acute Ischemic Stroke.

MRI machine learning mechanical thrombectomy mismatch outcome prediction perfusion imaging stroke

Journal

Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899

Informations de publication

Date de publication:
2022
Historique:
received: 07 07 2021
accepted: 28 03 2022
entrez: 13 6 2022
pubmed: 14 6 2022
medline: 14 6 2022
Statut: epublish

Résumé

Outcome prediction after mechanical thrombectomy (MT) in patients with acute ischemic stroke (AIS) and large vessel occlusion (LVO) is commonly performed by focusing on favorable outcome (modified Rankin Scale, mRS 0-2) after 3 months but poor outcome representing severe disability and mortality (mRS 5 and 6) might be of equal importance for clinical decision-making. We retrospectively analyzed patients with AIS and LVO undergoing MT from 2009 to 2018. Prognostic variables were grouped in baseline clinical (A), MRI-derived variables including mismatch [apparent diffusion coefficient (ADC) and time-to-maximum (Tmax) lesion volume] (B), and variables reflecting speed and extent of reperfusion (C) [modified treatment in cerebral ischemia (mTICI) score and time from onset to mTICI]. Three different scenarios were analyzed: (1) baseline clinical parameters only, (2) baseline clinical and MRI-derived parameters, and (3) all baseline clinical, imaging-derived, and reperfusion-associated parameters. For each scenario, we assessed prediction for favorable and poor outcome with seven different machine learning algorithms. In 210 patients, prediction of favorable outcome was improved after including speed and extent of recanalization [highest area under the curve (AUC) 0.73] compared to using baseline clinical variables only (highest AUC 0.67). Prediction of poor outcome remained stable by using baseline clinical variables only (highest AUC 0.71) and did not improve further by additional variables. Prediction of favorable and poor outcomes was not improved by adding MR-mismatch variables. Most important baseline clinical variables for both outcomes were age, National Institutes of Health Stroke Scale, and premorbid mRS. Our results suggest that a prediction of poor outcome after AIS and MT could be made based on clinical baseline variables only. Speed and extent of MT did improve prediction for a favorable outcome but is not relevant for poor outcome. An MR mismatch with small ischemic core and larger penumbral tissue showed no predictive importance.

Sections du résumé

Background and Purpose UNASSIGNED
Outcome prediction after mechanical thrombectomy (MT) in patients with acute ischemic stroke (AIS) and large vessel occlusion (LVO) is commonly performed by focusing on favorable outcome (modified Rankin Scale, mRS 0-2) after 3 months but poor outcome representing severe disability and mortality (mRS 5 and 6) might be of equal importance for clinical decision-making.
Methods UNASSIGNED
We retrospectively analyzed patients with AIS and LVO undergoing MT from 2009 to 2018. Prognostic variables were grouped in baseline clinical (A), MRI-derived variables including mismatch [apparent diffusion coefficient (ADC) and time-to-maximum (Tmax) lesion volume] (B), and variables reflecting speed and extent of reperfusion (C) [modified treatment in cerebral ischemia (mTICI) score and time from onset to mTICI]. Three different scenarios were analyzed: (1) baseline clinical parameters only, (2) baseline clinical and MRI-derived parameters, and (3) all baseline clinical, imaging-derived, and reperfusion-associated parameters. For each scenario, we assessed prediction for favorable and poor outcome with seven different machine learning algorithms.
Results UNASSIGNED
In 210 patients, prediction of favorable outcome was improved after including speed and extent of recanalization [highest area under the curve (AUC) 0.73] compared to using baseline clinical variables only (highest AUC 0.67). Prediction of poor outcome remained stable by using baseline clinical variables only (highest AUC 0.71) and did not improve further by additional variables. Prediction of favorable and poor outcomes was not improved by adding MR-mismatch variables. Most important baseline clinical variables for both outcomes were age, National Institutes of Health Stroke Scale, and premorbid mRS.
Conclusions UNASSIGNED
Our results suggest that a prediction of poor outcome after AIS and MT could be made based on clinical baseline variables only. Speed and extent of MT did improve prediction for a favorable outcome but is not relevant for poor outcome. An MR mismatch with small ischemic core and larger penumbral tissue showed no predictive importance.

Identifiants

pubmed: 35693017
doi: 10.3389/fneur.2022.737667
pmc: PMC9184444
doi:

Types de publication

Journal Article

Langues

eng

Pagination

737667

Informations de copyright

Copyright © 2022 Mutke, Madai, Hilbert, Zihni, Potreck, Weyland, Möhlenbruch, Heiland, Ringleb, Nagel, Bendszus and Frey.

Déclaration de conflit d'intérêts

VM reported receiving personal fees from ai4medicine outside the submitted work. AH reported receiving personal fees from ai4medicine outside the submitted work. DF reported receiving grants from the European Commission Horizon2020 PRECISE4Q No. 777107, reported receiving personal fees from and holding an equity interest in ai4medicine outside the submitted work. There is no connection, commercial exploitation, transfer, or association between the projects of ai4medicine and the results presented in this work. SN received unrelated fees for consultancy from Brainomix and Boehringer Ingelheim, payment for lectures including service on speakers' bureaus from Pfizer, Medtronic, and Bayer AG. MB received unrelated grants from Siemens, grants and personal fees from Novartis, grants from Stryker, grants from DFG, personal fees from Merck, personal fees from Bayer, personal fees from Teva, grants and personal fees from Guerbet, personal fees from Boehringer, personal fees from Vascular Dynamics, personal fees from Grifols, and grants from the European Union, all outside the submitted work. MMö received unrelated Board Membership from Codman; consultancy from Medtronic, MicroVention, and Stryker; payment for lectures including service on speakers bureaus' from Medtronic, MicroVention, and Stryker. PR received unrelated grants for consultancy from Boehringer and lecture fees from Bayer, Boehringer Ingelheim, BMS, Daichii Sankyo, and Pfizer. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Stroke. 2020 Dec;51(12):3541-3551
pubmed: 33040701
Front Neurol. 2018 Sep 25;9:784
pubmed: 30319525
J Cereb Blood Flow Metab. 2017 Sep;37(9):3176-3183
pubmed: 28029273
JAMA. 2016 Sep 27;316(12):1279-88
pubmed: 27673305
Neuroradiology. 2019 Jan;61(1):3-8
pubmed: 30357444
N Engl J Med. 2015 Mar 12;372(11):1009-18
pubmed: 25671797
PLoS One. 2020 Apr 6;15(4):e0231166
pubmed: 32251471
Lancet. 2016 Apr 23;387(10029):1723-31
pubmed: 26898852
Stroke. 2013 Sep;44(9):2650-63
pubmed: 23920012
AJNR Am J Neuroradiol. 2013 Jan;34(1):135-9
pubmed: 22837313
Int J Stroke. 2015 Apr;10(3):348-53
pubmed: 23802548
Front Neurol. 2020 Oct 15;11:580957
pubmed: 33178123
Stroke. 1999 Aug;30(8):1538-41
pubmed: 10436097
Lancet Neurol. 2019 Jan;18(1):46-55
pubmed: 30413385
Eur Radiol. 2019 Jul;29(7):3523-3532
pubmed: 30887195
Stroke. 2018 Apr;49(4):912-918
pubmed: 29540608
BMC Med Inform Decis Mak. 2020 Nov 30;20(1):310
pubmed: 33256715
Neuroimage Clin. 2021;29:102548
pubmed: 33450521
Neurology. 2018 Nov 20;91(21):e1951-e1960
pubmed: 30341155
AJNR Am J Neuroradiol. 2017 Mar;38(3):424-425
pubmed: 28104633
Stroke. 2020 Oct;51(10):3147-3155
pubmed: 32933417
Eur J Neurol. 2021 Apr;28(4):1234-1243
pubmed: 33220140

Auteurs

Matthias A Mutke (MA)

Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany.

Vince I Madai (VI)

Charité Lab for Artificial Intelligence in Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany.
QUEST (Quality, Ethics, Open Science, Translation) Center for Responsible Research at Berlin Institute of Health, Charité Universitätsmedizin Berlin, Berlin, Germany.
School of Computing and Digital Technology, Faculty of Computing, Engineering and the Built Environment, Birmingham City University, Birmingham, United Kingdom.

Adam Hilbert (A)

Charité Lab for Artificial Intelligence in Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany.

Esra Zihni (E)

Charité Lab for Artificial Intelligence in Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany.
School of Computing, Technological University Dublin, Dublin, Ireland.

Arne Potreck (A)

Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany.

Charlotte S Weyland (CS)

Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany.

Markus A Möhlenbruch (MA)

Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany.

Sabine Heiland (S)

Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany.

Peter A Ringleb (PA)

Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany.

Simon Nagel (S)

Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany.

Martin Bendszus (M)

Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany.

Dietmar Frey (D)

Charité Lab for Artificial Intelligence in Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany.

Classifications MeSH